Key Highlights
- Phase 3 EFZO-FIT study results published in The Lancet Respiratory Medicine, one of the highest-impact journals in pulmonary medicine
- Trial enrolled 268 patients with moderate to severe pulmonary sarcoidosis across global sites over 48 weeks
- Efzofitimod improved multiple patient-reported outcome measures including King's Sarcoidosis Questionnaire scores and Fatigue Assessment Scale
- Primary endpoint of steroid dose reduction was not met; lung function was preserved and drug was well-tolerated across both doses tested
aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company developing therapies derived from its tRNA synthetase platform, announced the publication of Phase 3 clinical results for its lead drug candidate efzofitimod in The Lancet Respiratory Medicine. The EFZO-FIT study, the largest randomized controlled trial ever conducted in pulmonary sarcoidosis, enrolled 268 patients and evaluated two doses of efzofitimod — 3.0 mg/kg and 5.0 mg/kg — versus placebo over 48 weeks, including a protocol-guided corticosteroid taper in the first 12 weeks.
Trial Results: PRO Improvements Despite Missing Primary Endpoint
The trial did not meet its primary endpoint of a statistically significant reduction in mean daily oral corticosteroid dose at week 48 versus placebo. However, the 5.0 mg/kg dose of efzofitimod demonstrated clinical benefit across multiple pre-specified patient-reported outcome measures. These included the King's Sarcoidosis Questionnaire Lung score, Fatigue Assessment Scale, King's Sarcoidosis Questionnaire General Health score, and the composite endpoint of complete steroid Withdrawal combined with KSQ-Lung improvement. Treatment with efzofitimod also maintained lung function as measured by forced vital capacity, a meaningful outcome given the progressive nature of sarcoidosis. The safety profile was described as consistent with earlier trials.
Significance of Lancet Publication
Publication in The Lancet Respiratory Medicine provides peer-reviewed validation of the trial's conduct, data quality, and findings. Lead author Daniel Culver of the Cleveland Clinic noted that the study's results are likely to lead to a paradigm shift in how sarcoidosis patients are managed with corticosteroids and how new therapies are evaluated in this disease area. The ability to substantially reduce steroid doses across all patients in the study, irrespective of drug assignment, was highlighted as a meaningful finding. aTyr CEO Sanjay Shukla characterized the publication as strengthening the evidence base for efzofitimod and increasing visibility for its differentiated profile.
Pipeline and Development Pathway
aTyr has initiated a new global Phase 3 study of efzofitimod in pulmonary sarcoidosis based on insights from EFZO-FIT, alongside a Phase 2 EFZO-CONNECT study evaluating the drug in systemic sclerosis-related interstitial lung disease. The company is advancing a pipeline targeting interstitial lung diseases characterized by inflammation and progressive fibrosis, where treatment Options remain limited. Efzofitimod's mechanism — selective modulation of activated myeloid cells through neuropilin-2 — represents a novel immunological approach that does not rely on broad immunosuppression.
The Lancet publication positions aTyr as a meaningful contributor to the scientific discourse on sarcoidosis therapy, a disease affecting approximately 160,000 Americans for which steroid therapy remains the predominant but often inadequate standard of care. Continued Investment in the development program reflects management's conviction that efzofitimod's PRO profile and tolerability data provide a viable pathway to regulatory approval.





_11_19_2026_18_29_00_678569.jpg)
Please wait processing your request...